You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Simultaneous and divergent evolution of resistance to cephalosporin/β-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomonas aeruginosa infections
|
|---|---|
| Published in |
Journal of Antimicrobial Chemotherapy (JAC), March 2023
|
| DOI | 10.1093/jac/dkad062 |
| Pubmed ID | |
| Authors |
Isaac Alonso-García, Juan Carlos Vázquez-Ucha, Cristina Lasarte-Monterrubio, Elena González-Mayo, Paula Lada-Salvador, Ramón Vela-Fernández, Pablo Aja-Macaya, Paula Guijarro-Sánchez, Soraya Rumbo-Feal, María Muíño-Andrade, Ana Fernández-González, Marta Martínez-Guitián, Alejandro Beceiro, Manuel Rodríguez-Iglesias, Antonio Oliver, Jorge Arca-Suárez, Fátima Galán-Sánchez, Germán Bou |
| Abstract |
To describe and characterize the emergence of resistance to ceftolozane/tazobactam, ceftazidime/avibactam and imipenem/relebactam in a patient receiving ceftazidime/avibactam treatment for an MDR Pseudomonas aeruginosa CNS infection. One baseline (PA1) and two post-exposure (PA2 and PA3) isolates obtained before and during treatment of a nosocomial P. aeruginosa meningoventriculitis were evaluated. MICs were determined by broth microdilution. Mutational changes were investigated through WGS. The impact on β-lactam resistance of mutations in blaPDC and mexR was determined through cloning experiments and complementation assays. Isolate PA1 showed baseline resistance mutations in DacB (I354A) and OprD (N142fs) conferring resistance to conventional antipseudomonals but susceptibility to ceftazidime/avibactam, ceftolozane/tazobactam and imipenem/relebactam. Post-exposure isolates showed two divergent ceftazidime/avibactam-resistant phenotypes associated with distinctive mutations affecting the intrinsic P PDC β-lactamase (S254Ins) (PA2: ceftolozane/tazobactam and ceftazidime/avibactam-resistant) or MexAB-OprM negative regulator MexR in combination with modification of PBP3 (PA3: ceftazidime/avibactam and imipenem/relebactam-relebactam-resistant). Cloning experiments demonstrated the role of PDC modification in resistance to ceftolozane/tazobactam and ceftazidime/avibactam. Complementation with a functional copy of the mexR gene in isolate PA3 restored imipenem/relebactam susceptibility. We demonstrated how P. aeruginosa may simultaneously develop resistance and compromise the activity of new β-lactam/β-lactamase inhibitor combinations when exposed to ceftazidime/avibactam through selection of mutations leading to PDC modification and up-regulation of MexAB-OprM-mediated efflux. |
X Demographics
The data shown below were collected from the profiles of 15 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 6 | 40% |
| Unknown | 9 | 60% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 12 | 80% |
| Scientists | 2 | 13% |
| Science communicators (journalists, bloggers, editors) | 1 | 7% |
Mendeley readers
The data shown below were compiled from readership statistics for 21 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 21 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 3 | 14% |
| Researcher | 3 | 14% |
| Lecturer | 2 | 10% |
| Student > Ph. D. Student | 2 | 10% |
| Student > Doctoral Student | 1 | 5% |
| Other | 2 | 10% |
| Unknown | 8 | 38% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 4 | 19% |
| Immunology and Microbiology | 3 | 14% |
| Nursing and Health Professions | 1 | 5% |
| Unspecified | 1 | 5% |
| Energy | 1 | 5% |
| Other | 1 | 5% |
| Unknown | 10 | 48% |
Attention Score in Context
This research output has an Altmetric Attention Score of 17. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 May 2023.
All research outputs
#2,186,537
of 25,411,814 outputs
Outputs from Journal of Antimicrobial Chemotherapy (JAC)
#764
of 8,180 outputs
Outputs of similar age
#44,334
of 426,976 outputs
Outputs of similar age from Journal of Antimicrobial Chemotherapy (JAC)
#10
of 99 outputs
Altmetric has tracked 25,411,814 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 8,180 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.9. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 426,976 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 99 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.